Undiagnosed dysglycemia in patients hospitalized for worsening heart failure: not so sweet after all

Chioncel, Ovidiu; Ambrosy, Andrew P.

doi:10.1177/2047487318810561

Cited by 1 publication

(1 citation statement)

References 21 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…54,55 In general cardiology clinics, 19% to 26% of diabetes and 22% to 43% of prediabetes patients remain undiagnosed. 56 It is important to note that CV events and renal dysfunction occur during the undiagnosed phase of prediabetes and years before the diagnosis of T2DM. Thus, early detection and risk factor modification are crucial in preventing further complications.…”

Section: Introductionmentioning

confidence: 99%

Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action

Sabbour

Ahmad

2023

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

Background: Heart failure (HF) is an important adverse outcome of diabetes mellitus (DM) with high rates of mortality and HF-related hospitalizations. The risk of HF is 2 times higher in patients with DM compared to those without DM. Due to under-recognition and underdiagnoses, HF is often a neglected outcome in the diabetic population. There is a dearth of data regarding the true prevalence of HF and the management protocols for diabetic patients at risk of HF in the UAE and the Middle East. This lacuna in the information has led to the inception of this “call to action” paper, which identifies the gaps in the true prevalence of HF and describes the importance of early diagnosis and appropriate management of HF in the Middle East. Methodology: An advisory board meeting was convened and a group of key opinion leaders and experts in cardiology and endocrinology assembled to describe the prevalence, diagnosis, and management of HF in diabetes patients and to present a “call to action” in the UAE and Middle East scenario. After the group discussion, key expert opinions were formulated and “call to action” recommendations were proposed. Conclusion: This “call to action” is mainly based on the available evidence from the literature and the experts’ clinical experience. Based on the new evidence from various cardiovascular outcome trials, the “call to action” highlights a series of collaborative learning regarding the role of newer antidiabetic therapies like sodium–glucose cotransporter-2 inhibitors in the prevention and management of HF. This “call to action” intends to serve as a guide for physicians, including primary healthcare providers, in their management of diabetic patients with HF.

show abstract

Section: Introductionmentioning

confidence: 99%